# Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)

Study · id `cardio:ct-nct06959784` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06959784](<https://clinicaltrials.gov/study/NCT06959784>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06959784

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 142 participants.

## Technical summary

Registry record NCT06959784. Randomized; no masking; primary purpose treatment. Start 2024-01-01 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 142 participants (planned count; ClinicalTrials.gov record NCT06959784, source copy `cardio:ctgov-nct06959784-2025-05-07`, retrieved 2026-10-26)
- Started: 2024-01-01 (actual) (ClinicalTrials.gov record NCT06959784, source copy `cardio:ctgov-nct06959784-2025-05-07`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06959784, source copy `cardio:ctgov-nct06959784-2025-05-07`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06959784, source copy `cardio:ctgov-nct06959784-2025-05-07`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06959784, source copy `cardio:ctgov-nct06959784-2025-05-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ENROLLING\_BY\_INVITATION" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06959784-2025-05-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)
- Condition: Diabetes Mellitus
- Condition: Cardiovascular Diseases
- Condition: Cerebrovascular Disease
- Intervention (Drug): semaglutide
- Intervention (Drug): Metformin
- Lead sponsor: China-Japan Friendship Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: China-Japan Friendship Hospital (`cardio:org-china-japan-friendship-hospital`)

## Provenance

Content hash: 568cc148a5636eb8b53dd4ce1bcdef9146b721608f1bb6abbea079c9c0aa69e6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
